314 related articles for article (PubMed ID: 31023616)
1. Vasoconstrictors in hepatorenal syndrome - A critical review.
Mattos ÂZ; Schacher FC; Mattos AA
Ann Hepatol; 2019; 18(2):287-290. PubMed ID: 31023616
[TBL] [Abstract][Full Text] [Related]
2. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
Moreau R; Lebrec D
Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
[TBL] [Abstract][Full Text] [Related]
3. Hepatorenal syndrome: the clinical impact of vasoactive therapy.
Colle I; Laterre PF
Expert Rev Gastroenterol Hepatol; 2018 Feb; 12(2):173-188. PubMed ID: 29258378
[TBL] [Abstract][Full Text] [Related]
4. Noradrenaline as an alternative medical treatment to terlipressin in the management of hepatorenal syndrome type 1.
Sendra C; Silva Ruiz MDP; Ferrer Rios MT; Alarcón García JC; Pascasio Acevedo JM
Gastroenterol Hepatol; 2018; 41(7):440-441. PubMed ID: 29054321
[No Abstract] [Full Text] [Related]
5. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
Garcia-Tsao G; Abraldes JG; Rich NE; Wong VW
Gastroenterology; 2024 Jan; 166(1):202-210. PubMed ID: 37978969
[TBL] [Abstract][Full Text] [Related]
6. Hepatorenal syndrome: Current concepts related to diagnosis and management.
de Mattos ÁZ; de Mattos AA; Méndez-Sánchez N
Ann Hepatol; 2016; 15(4):474-81. PubMed ID: 27236146
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
Facciorusso A; Chandar AK; Murad MH; Prokop LJ; Muscatiello N; Kamath PS; Singh S
Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):94-102. PubMed ID: 28403995
[TBL] [Abstract][Full Text] [Related]
8. Vasoconstrictor therapy for hepatorenal syndrome in liver cirrhosis.
Schmidt LE; Ring-Larsen H
Curr Pharm Des; 2006; 12(35):4637-47. PubMed ID: 17168767
[TBL] [Abstract][Full Text] [Related]
9. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.
Gifford FJ; Morling JR; Fallowfield JA
Aliment Pharmacol Ther; 2017 Mar; 45(5):593-603. PubMed ID: 28052382
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective.
Carter JA; Huang X; Jamil K; Corman S; Ektare V; Niewoehner J
J Med Econ; 2023; 26(1):1342-1348. PubMed ID: 37729445
[TBL] [Abstract][Full Text] [Related]
11. Current Pharmacologic Therapies for Hepatorenal Syndrome-Acute Kidney Injury.
Duong N; Kakadiya P; Bajaj JS
Clin Gastroenterol Hepatol; 2023 Sep; 21(10S):S27-S34. PubMed ID: 37625864
[TBL] [Abstract][Full Text] [Related]
12. Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal haemorrhage.
Döhler KD; Meyer M
Best Pract Res Clin Anaesthesiol; 2008 Jun; 22(2):335-50. PubMed ID: 18683479
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
Krag A; Borup T; Møller S; Bendtsen F
Adv Ther; 2008 Nov; 25(11):1105-40. PubMed ID: 19018483
[TBL] [Abstract][Full Text] [Related]
14. Terlipressin in the management of adults with hepatorenal syndrome-acute kidney injury (HRS-AKI).
Kulkarni AV; Lee J; Reddy KR
Expert Rev Gastroenterol Hepatol; 2023; 17(11):1067-1079. PubMed ID: 37856367
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of treatment with terlipressin plus albumin in hepatorenal syndrome diagnosed with the new acute kidney injury versus the conventional criteria.
Kalambokis GN; Christaki M; Tsiakas I; Despotis G; Milionis HJ
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1292-1294. PubMed ID: 31498285
[No Abstract] [Full Text] [Related]
16. Management of ascites and hepatorenal syndrome.
Piano S; Tonon M; Angeli P
Hepatol Int; 2018 Feb; 12(Suppl 1):122-134. PubMed ID: 28836115
[TBL] [Abstract][Full Text] [Related]
17. Terlipressin versus other vasoactive drugs for hepatorenal syndrome.
Israelsen M; Krag A; Allegretti AS; Jovani M; Goldin AH; Winter RW; Gluud LL
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011532. PubMed ID: 28953318
[TBL] [Abstract][Full Text] [Related]
18. Hepatorenal syndrome.
Biswas KD; Jain AK
Trop Gastroenterol; 2002; 23(3):113-6. PubMed ID: 12693150
[TBL] [Abstract][Full Text] [Related]
19. Hepatorenal syndrome and novel advances in its management.
Fabrizi F; Aghemo A; Messa P
Kidney Blood Press Res; 2013; 37(6):588-601. PubMed ID: 24356549
[TBL] [Abstract][Full Text] [Related]
20. [Vasoconstrictors in the treatment of hepatorenal syndrome].
Ortega R; Calahorra B; Ginès P
Nefrologia; 2002; 22 Suppl 5():56-61. PubMed ID: 12107919
[No Abstract] [Full Text] [Related]
[Next] [New Search]